Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries AGILON HEALTH (NYSE: AGL) INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies Agilon Health Investors of a Class Action Lawsuit and May 20, 2024 Lead Plaintiff Deadline By: NewMediaWire May 09, 2024 at 17:12 PM EDT NEW YORK, NY - (NewMediaWire) - May 9, 2024 - Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) reminds investors that a complaint has been filed on behalf of purchasers or acquirers of agilon health, Inc. (“agilon” or the “Company”) (NYSE: AGL) common stock between April 15, 2021 and February 27, 2024. Click Here to Join Investigation.If you acquired agilon common stock during the Class Period and have suffered losses, you may click here to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003.Deadline Reminder: If you are a member of the proposed Class, you may move the court no later than May 20, 2024 to serve as a lead plaintiff for the purported class. If you have losses, we encourage you to contact us to learn more about the lead plaintiff process.According to the complaint, investors began to learn the truth about the cost pressures impacting the Company’s medical margin and profitability on November 2, 2023, when the Company announced its third quarter 2023 financial results after the market closed. Critically, agilon reported a net loss of $31 million for the third quarter of 2023 and slashed its fiscal year 2023 medical margin outlook by approximately $50 million to a range between $455 million and $470 million.Following this news, the price of agilon stock fell $2.23, or 13.2%, to close at $14.66 per share on November 3, 2023.Then, on January 5, 2024, according to the complaint, investors more fully learned the truth when agilon further slashed its 2023 medical margin guidance by more than $100 million, to a range between $340 million and $360 million due to “higher-than-expected medical costs.” Additionally, agilon disclosed that its Chief Financial Officer, Timothy Bensley, would retire in 2024.Following this news, agilon's stock price fell $3.45 per share, nearly 29%, to close at $8.63 per share on January 5, 2024.WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.If you have any questions about this Notice, your rights, or your interests, please contact:Pamela A. MayerKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(646) 315-9003E-mail: pmayer@kaplanfox.comLaurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1560Oakland, California 94612(415) 772-4704Fax: (415) 772-4707E-mail: lking@kaplanfox.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
AGILON HEALTH (NYSE: AGL) INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies Agilon Health Investors of a Class Action Lawsuit and May 20, 2024 Lead Plaintiff Deadline By: NewMediaWire May 09, 2024 at 17:12 PM EDT NEW YORK, NY - (NewMediaWire) - May 9, 2024 - Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) reminds investors that a complaint has been filed on behalf of purchasers or acquirers of agilon health, Inc. (“agilon” or the “Company”) (NYSE: AGL) common stock between April 15, 2021 and February 27, 2024. Click Here to Join Investigation.If you acquired agilon common stock during the Class Period and have suffered losses, you may click here to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003.Deadline Reminder: If you are a member of the proposed Class, you may move the court no later than May 20, 2024 to serve as a lead plaintiff for the purported class. If you have losses, we encourage you to contact us to learn more about the lead plaintiff process.According to the complaint, investors began to learn the truth about the cost pressures impacting the Company’s medical margin and profitability on November 2, 2023, when the Company announced its third quarter 2023 financial results after the market closed. Critically, agilon reported a net loss of $31 million for the third quarter of 2023 and slashed its fiscal year 2023 medical margin outlook by approximately $50 million to a range between $455 million and $470 million.Following this news, the price of agilon stock fell $2.23, or 13.2%, to close at $14.66 per share on November 3, 2023.Then, on January 5, 2024, according to the complaint, investors more fully learned the truth when agilon further slashed its 2023 medical margin guidance by more than $100 million, to a range between $340 million and $360 million due to “higher-than-expected medical costs.” Additionally, agilon disclosed that its Chief Financial Officer, Timothy Bensley, would retire in 2024.Following this news, agilon's stock price fell $3.45 per share, nearly 29%, to close at $8.63 per share on January 5, 2024.WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.If you have any questions about this Notice, your rights, or your interests, please contact:Pamela A. MayerKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(646) 315-9003E-mail: pmayer@kaplanfox.comLaurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1560Oakland, California 94612(415) 772-4704Fax: (415) 772-4707E-mail: lking@kaplanfox.com
NEW YORK, NY - (NewMediaWire) - May 9, 2024 - Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) reminds investors that a complaint has been filed on behalf of purchasers or acquirers of agilon health, Inc. (“agilon” or the “Company”) (NYSE: AGL) common stock between April 15, 2021 and February 27, 2024. Click Here to Join Investigation.If you acquired agilon common stock during the Class Period and have suffered losses, you may click here to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003.Deadline Reminder: If you are a member of the proposed Class, you may move the court no later than May 20, 2024 to serve as a lead plaintiff for the purported class. If you have losses, we encourage you to contact us to learn more about the lead plaintiff process.According to the complaint, investors began to learn the truth about the cost pressures impacting the Company’s medical margin and profitability on November 2, 2023, when the Company announced its third quarter 2023 financial results after the market closed. Critically, agilon reported a net loss of $31 million for the third quarter of 2023 and slashed its fiscal year 2023 medical margin outlook by approximately $50 million to a range between $455 million and $470 million.Following this news, the price of agilon stock fell $2.23, or 13.2%, to close at $14.66 per share on November 3, 2023.Then, on January 5, 2024, according to the complaint, investors more fully learned the truth when agilon further slashed its 2023 medical margin guidance by more than $100 million, to a range between $340 million and $360 million due to “higher-than-expected medical costs.” Additionally, agilon disclosed that its Chief Financial Officer, Timothy Bensley, would retire in 2024.Following this news, agilon's stock price fell $3.45 per share, nearly 29%, to close at $8.63 per share on January 5, 2024.WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.If you have any questions about this Notice, your rights, or your interests, please contact:Pamela A. MayerKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(646) 315-9003E-mail: pmayer@kaplanfox.comLaurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1560Oakland, California 94612(415) 772-4704Fax: (415) 772-4707E-mail: lking@kaplanfox.com